Company profile
ARYx Therapeutics, Inc.
OTC: ARYX · Healthcare · Drug Manufacturers - Specialty & Generic
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 48
v0.1 · 5/100 weight · pillars only
↑ listing tenure, workforce scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$33.2M
Employees
56
as of 2026-08-29
Market cap
$16.7k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02009
Net income-$33.2M-$33.2M2009
Operating income-$31.2M-$31.2M2009
Total assets$12.4M$12.4M2009
Liabilities$15.3M$15.3M2009
Equity-$2.9M-$2.9M2009
Revenue trend
FY2003 – FY2009 · USD
FY03
FY04
FY05
FY06
FY07
FY08
FY09
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ARYx Therapeutics, Inc.’s revenue?
ARYx Therapeutics, Inc. booked $0 in FY2009 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Scopus BioPharma Inc.——Healthcare Solutions Management Group, Inc.——Stem Cell Authority, Ltd.——VioQuest Pharmaceuticals, Inc.——Golden Developing Solutions, Inc.——CNBX Pharmaceuticals Inc.18DNeighbors
Alameda →Key facts
CEOPaul Goddard
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersFremont, CA
ExchangeOTC: ARYX
Employees56
IPO date2007-11-07
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.